Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 7/20 | 0.44 |
| ▸ | CYBB | P04839 | 2/20 | 0.43 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9184287 | 0.92 | NCF1 (0.46) | HTR1AHTR1DHTR1BMAPTKDM4E | |
| SCHEMBL9186984 | 0.90 | NCF1 (0.49) | HTR1AHTR1DHTR1BMAPTKDM4E | |
| SCHEMBL23412378 | 0.89 | MAPT (0.52) | HTR1AHTR1DHTR1BMAPTKDM4E | |
| SCHEMBL2164367 | 0.89 | NCF1 (0.51) | HTR1AHTR1DHTR1BMAPTKDM4E | |
| SCHEMBL23412188 | 0.87 | NCF1 (0.51) | HTR1AHTR1DHTR1BMAPTKDM4E | |
| SCHEMBL23412437 | 0.86 | NCF1 (0.58) | HTR1AHTR1DHTR1BMAPTKDM4E | |
| SCHEMBL23412668 | 0.84 | NCF1 (0.59) | MAPTKDM4ENCF1CYBBNOX5 | |
| SCHEMBL23412394 | 0.84 | NCF1 (0.59) | MAPTKDM4ENCF1CYBBNOX5 | |
| SCHEMBL23412286 | 0.84 | NCF1 (0.59) | MAPTKDM4ENCF1CYBBNOX5 | |
| SCHEMBL19941005 | 0.83 | HTR1B (0.59) | HTR1AHTR1DHTR1BMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244726-B2 | Heterocyclic compounds possessing affinity at 5HT1 -type receptors and use thereof in therapy | GLAXO GROUP LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-7214674-B2 | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| EP-1480972-B1 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2007-04-11 | — | — | EP | disclosed |
| EP-1330460-B1 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-21 | — | — | EP | disclosed |
| EP-1476444-B1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2006-04-12 | — | — | EP | disclosed |
| US-6939871-B2 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| US-20050153974-A1 | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| US-20050085458-A1 | Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy | GLAXO GROUP LIMITED (GB) | 2005-04-21 | — | — | US | disclosed |
| WO-2003068236-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| EP-1330460-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002034754-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-02 | — | — | WO | disclosed |
| US-6130217-A | ANTITUMOR | PFIZER INC (US) | 2000-10-10 | — | — | US | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| WO-1994022846-A1 | COMPOUNDS ENHANCING ANTITUMOR ACTIVITY OF OTHER CYTOTOXIC AGENTS | PFIZER INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | HTR5A, HTR2C, HTR3C | HTR1A 4/4885HTR1D 9/4885HTR1B 8/4885 |
| US-20050153974-A1 | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors | HTR1A, HTR1D, HTR2C | HTR1A 1/4885HTR1D 2/4885HTR1B 11/4885 |
| US-20050085458-A1 | Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy | HTR3C, HTR1A, HTR2C | HTR1A 2/4885HTR1D 4/4885HTR1B 11/4885 |
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | CNR1, HTR5A, HTR1A | HTR1A 3/4885HTR1D 6/4885HTR1B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.